Search peptides, terms, sources/
Repair and regeneration

TB-500

Also known as: Thymosin Beta-4 fragment · T-beta-4 fragment

Short synthetic fragment linked to thymosin beta-4. Not licensed in the UK. No human trials of TB-500 itself were found; trials of the full-length protein are not evidence for it.

UK status and evidence last reviewed .

UK status
Not licensed in the UKChecked

Evidence grade: best single recorded finding

How grading works

Best recorded finding: Limited evidence (level 2 of 4 on our scale)

This grades the evidence behind one recorded finding. It does not rate the compound.

1 finding at this grade. See all findings

These labels summarise the recorded evidence and the UK regulatory position. They are not recommendations. None of them means a product is safe to obtain or use, and none of them means a product is licensed or lawful to supply. TB-500 is recorded as not licensed in the UK (checked 14 November 2026).

Best study type
Animal studies1 combination study (with BPC-157) · 1 animal

What is TB-500?

TB-500 is a short synthetic fragment described as representing part of thymosin beta-4, a natural protein studied in tissue healing. It is not licensed in the UK, no human trials of TB-500 itself were found, and trials of full-length thymosin beta-4 exist but are not evidence for TB-500.

It is described as the actin-binding region of thymosin beta-4. Trials of full-length thymosin beta-4 are covered on their own profile.

Class
Actin-sequestering peptide fragment (thymosin beta-4 family)
Origin
Fragment / derived
Research areas
Healing & Recovery
UK status
Not licensed in the UK
Best study type
Animal studies
Evidence last reviewed

How does TB-500 work?

Thymosin beta-4 binds actin, a protein that gives cells their shape and movement. This is linked to less inflammation, new blood vessel growth and cell migration. These findings are for the full-length protein. Whether the fragment known as TB-500 acts the same way has not been confirmed.

The mechanism in more detail

A note before the mechanism: no human trial of TB-500 itself was found. Human trials have used full-length thymosin beta-4 (codes RGN-137 and RGN-259), applied as a gel or eye drop, and those are covered on the thymosin beta-4 profile. TB-500 is described as a shorter synthetic fragment of the thymosin beta-4 sequence. The two are not the same molecule. The mechanism below describes thymosin beta-4 biology generally, not a tested effect of TB-500.

Thymosin beta-4 is described in the research literature as the major actin-sequestering molecule in mammalian cells, meaning it binds free actin protein and helps regulate the cell’s internal cytoskeleton. This activity has been linked, in preclinical and some human studies, to several downstream effects: reduced inflammatory chemokine and cytokine signalling, promotion of new blood-vessel formation (angiogenesis), support for cell migration and survival, and involvement in stem-cell maturation. No single dedicated receptor for this activity has been identified in the literature reviewed; the mechanism is understood as largely intracellular rather than receptor-mediated.

A 2026 scoping review mapping 80 studies of thymosin beta-4 and TB-500 found the most consistent evidence for these mechanisms in wound, skin and soft-tissue healing, vascular and endothelial repair, and corneal or ocular tissue, while evidence specific to musculoskeletal tissue (tendon, ligament, muscle, cartilage) was comparatively sparse. This is a meaningful gap between the peptide’s popular reputation as a tendon and recovery peptide and what has actually been studied, and it should be read alongside the fragment and route caveat above, not in isolation.

Classification and structure

Names
TB-500; Thymosin Beta-4 fragment; T-beta-4 fragment (17-23 region)
Class
Actin-sequestering peptide fragment (thymosin beta-4 family)
Origin
Fragment / derived
Routes used in the research
Human RCTs of full-length thymosin beta-4 used topical application (gel formulation for dermal, venous and pressure ulcers) and topical ophthalmic drops for corneal work. Preclinical rodent studies of TB-500 more typically used subcutaneous or intraperitoneal injection; the one retrospective human case series used intra-articular injection. This route disparity between the trial evidence and injectable TB-500 is a material caveat, separate from the fragment-versus-full-length molecule issue, and neither is a usage instruction.How the substance was given in the studies cited on this page. This describes study methods only. It is not guidance on use.

What does the research show?

TB-500 has 2 recorded research findings. Each shows how strong it is, the kind of study behind it, its source and its main limitation.

Findings by strength of evidence

2 findings

Counts recorded findings by grade. It does not rate the compound.

Findings by strength of evidence
PreliminaryLimitedModerateStrongNot graded
11000

2026 scoping review, 80 studies Limited

A 2026 peer-reviewed scoping review mapped 80 studies of thymosin beta-4 and TB-500 in tissue healing. Most of the studies tested full-length thymosin beta-4, not TB-500, and most were lab or animal work. Direct evidence on TB-500 itself came from a single included study. Human evidence was mainly in eye and skin-wound settings, and direct evidence for tendon, ligament, muscle and cartilage was sparse.

Study type
Animal
Population
Mixed preclinical (rodent, ex-vivo) and human clinical across 80 studies
Source
1 McGuire et al., 2026

Limitation: A scoping review maps the literature landscape rather than pooling a specific outcome, and does not report a GRADE-style certainty rating.

Limitations in full

A scoping review maps the literature landscape rather than pooling a specific outcome, and does not report a GRADE-style certainty rating. It does incorporate genuine human RCT evidence for several mapped indications. The review's own finding that musculoskeletal-specific evidence is comparatively sparse directly complicates the recovery and tendon framing TB-500 carries in public discussion.

Combined BPC-157 chart review Preliminary Combination, not TB-500 alone

A retrospective chart review (shared population with the BPC-157 dossier) found that of 4 knee-pain patients who received combined intra-articular BPC-157 and TB-500, 3 of 4 (75%) reported significant improvement; 1 of 4 had no relief.

Study type
Human observational
Population
Human, retrospective chart review, n=4 (combined-therapy subgroup of a 16-patient cohort)
Source
2 Lee et al., 2021

Limitation: n=4 is very small even by the standards of an already-small retrospective series.

Limitations in full

n=4 is very small even by the standards of an already-small retrospective series. Combined therapy means the effect cannot be attributed to TB-500 specifically rather than BPC-157 or the combination. No control group; retrospective and unblinded.

What safety findings have been reported?

1 safety finding is recorded for TB-500. A short list does not mean a substance is safe; it reflects what has been studied and reported.

Phase 1, 40 volunteers (full-length thymosin beta-4)

A randomised, placebo-controlled Phase 1 study gave intravenous synthetic full-length thymosin beta-4 to 40 healthy volunteers. Adverse events were infrequent and mild or moderate, with no serious adverse events. That is too few people to rule out rarer harms. This tested full-length thymosin beta-4, not TB-500, so it does not show how TB-500 behaves in people.

Source
3 Ruff et al., 2010

What is TB-500's UK regulatory status?

Marketing authorisation
No UK marketing authorisation found. Full-length thymosin beta-4 products (RGN-137, RGN-259) have been tested in trials up to Phase 3; no approval for either was found. A check of the MHRA Products database active substance index on 14 November 2026 found no entry for TB-500 or thymosin beta-4.
Prescription status
Not applicable, no licensed UK product was found to classify.
Medicine class
Not classified as a licensed medicine.
MHRA position
Not a controlled substance under the Misuse of Drugs Act 1971. Whether a specific product is a medicinal product is a case-by-case MHRA determination under the Human Medicines Regulations 2012, based on presentation and claims made. No TB-500-specific MHRA enforcement notice or Yellow Card FOI data was located.
Authorised use
None.
Other restrictions
In sport, the WADA 2026 Prohibited List (in force from 1 January 2026) names thymosin beta-4 and its derivatives, for example TB-500, under S2.3, growth factors, prohibited at all times.

These labels summarise the recorded evidence and the UK regulatory position. They are not recommendations. None of them means a product is safe to obtain or use, and none of them means a product is licensed or lawful to supply. TB-500 is recorded as not licensed in the UK (checked 14 November 2026).

References

4 sources, numbered as cited above. Each has its own page with its limitations and everything that cites it.

  1. McGuire F, Hughes E, Maak T, Cushman DM (2026). Thymosin Beta-4 and TB-500 in Tissue Healing, Regeneration, and Musculoskeletal Repair, A Scoping Review. Applied Sciences (MDPI)Scoping review · DOI 10.3390/app16126202 · Original ↗
  2. Lee E, Padgett B (2021). Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Alternative Therapies in Health and MedicineHuman observational · PMID 34324435 · Original ↗
  3. Ruff D, Crockford D, Girardi G, Zhang Y (2010). A randomized, placebo-controlled, single and multiple dose study of intravenous thymosin beta4 in healthy volunteers. Annals of the New York Academy of SciencesRCT, Human clinical trial · DOI 10.1111/j.1749-6632.2010.05474.x · PMID 20536472 · Original ↗
  4. Medicines and Healthcare products Regulatory Agency (MHRA) (2026). MHRA Products database: active substance index (A to Z), checked 14 November 2026. MHRA Products database · Original ↗

Questions about TB-500

What is TB-500?

TB-500 is a short synthetic fragment described as representing part of thymosin beta-4, a natural protein studied in tissue healing. It is not licensed in the UK, no human trials of TB-500 itself were found, and trials of full-length thymosin beta-4 exist but are not evidence for TB-500. Read what it is.

Is TB-500 licensed in the UK?

PeptGuru records TB-500's UK status as: Not licensed in the UK. No UK marketing authorisation found. UK status checked 14 November 2026. This is a record of regulation, not a recommendation. Read the UK status.

What does the research on TB-500 show?

PeptGuru records 2 research findings for TB-500: 1 from a human observational study and 1 from an animal study. Each finding has its own evidence grade, source and main limitation. Read the research findings.

What safety findings have been reported for TB-500?

1 safety finding is recorded, including: phase 1, 40 volunteers (full-length thymosin beta-4). Each is cited to its source. A short list does not mean a substance is safe. Read the safety findings.

Where are the sources for TB-500?

All 4 sources are listed in the references, each with a link to the original study or regulator document and its own source page on PeptGuru. See the references.

Review record and change log

Last reviewed
Evidence last reviewed
UK status checked
Reviewed by
PeptGuru editorial team
  • Regulatory update · Sport status confirmed from WADA's own 2026 Prohibited List (S2.3, thymosin beta-4 and its derivatives).
  • Correction · Removed a venous-ulcer trial finding: it tested full-length thymosin beta-4, not TB-500, and cited a trial-design paper rather than the results. Some figures in it were not in the published results. The Phase 1 safety finding now cites the original study. The scoping-review finding now says plainly that direct TB-500 evidence is a single study.

How findings are graded: the grading method. All changes.

  • Thymosin beta-4Thymosin β4

    Natural 43-amino-acid peptide studied in eye and wound-healing trials. Not licensed in the UK. Trials were small with mixed results. It is not TB-500.

    Repair and regenerationHuman trialsEvidence reviewed
    LimitedNot licensed in the UK
  • BPC-157Body Protection Compound-157

    Synthetic gastric-derived peptide studied in animal models of tissue healing. Not licensed in the UK; human evidence is one small uncontrolled study.

    Repair and regenerationHuman observationalEvidence reviewed
    LimitedNot licensed in the UK
  • GHK-CuCopper peptide GHK

    Copper-binding tripeptide studied for skin ageing and wound healing. Topical cosmetic use; no licensed injectable product in the UK.

    Repair and regenerationHuman trialsEvidence reviewed
    LimitedNot licensed in the UK
  • KPVLys-Pro-Val

    Three-amino-acid fragment of alpha-MSH, studied in cell and mouse models of inflammation. Not licensed in the UK. No human trial of KPV was found.

    Immune and longevityAnimal studiesEvidence reviewed
    PreliminaryNot licensed in the UK

Compare TB-500 with Thymosin beta-4

Spotted an error? Report a problem with this page. We correct the record and log every change on What's changed.